PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 88.41

Change

+0.11 (+0.12)%

Market Cap

N/A

Volume

6.80K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.26 (-0.17%)

USD 42.19B
FHLC Fidelity® MSCI Health Care In..

-0.02 (-0.03%)

USD 3.02B
FXH First Trust Health Care AlphaD..

-0.02 (-0.02%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.11 (-0.12%)

USD 0.22B
IDNA iShares Genomics Immunology an..

-0.09 (-0.38%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.40 (+1.07%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.43 (+0.44%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.05 (-0.17%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

-0.19 (-0.29%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.22 (+0.76%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.18% 90% A- 76% C+
Dividend Return 0.50% 60% D- 9% A-
Total Return 16.68% 90% A- 73% C
Trailing 12 Months  
Capital Gain 17.10% 43% F 61% D-
Dividend Return 0.76% 44% F 9% A-
Total Return 17.86% 43% F 55% F
Trailing 5 Years  
Capital Gain 52.51% 67% D+ 73% C
Dividend Return 4.03% 56% F 11% F
Total Return 56.54% 62% D 69% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.52% 57% F 60% D-
Dividend Return 7.12% 57% F 55% F
Total Return 0.59% 58% F 13% F
Risk Return Profile  
Volatility (Standard Deviation) 12.87% 67% D+ 70% C-
Risk Adjusted Return 55.29% 67% D+ 73% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike